echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's Oral S1P Modulator for Ulcerative Colitis Meets Primary Endpoint of Phase 3 Clinical Trial

    Pfizer's Oral S1P Modulator for Ulcerative Colitis Meets Primary Endpoint of Phase 3 Clinical Trial

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 23, 2022, Pfizer announced positive top-line results from a Phase 3 clinical trial of etrasimod (ADP334)


    UC is a chronic, often debilitating inflammatory bowel disease


    Etrasimod was developed by Arena Pharmaceuticals, which was acquired by Pfizer in December


    Image source: Pfizer's official website

    This multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial enrolled 354 patients with UC who had previously failed or were intolerant to at least one conventional therapy/biologic/JAK therapy


    References:

    [1] Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.